Cargando…

Compared to preoperative plasma levels post-operative urokinase-type plasminogen activator-1 levels are persistently elevated for 6 weeks after minimally invasive colorectal resection

BACKGROUND: Urokinase-type plasminogen activator-1 (uPA) is a serine protease that converts plasminogen to plasmin after binding to uPA receptor (uPAR). Plasmin catalyzes the regeneration of basement membrane, extracellular matrix, and other tissues. uPA alone and with plasmin leads to activation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shantha Kumara, HMC, Poppy, Addison, Gamage, Dasuni N., Mitra, Neil, Yan, Xiaohong, Hedjar, Yanni, Cekic, Vesna, Whelan, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007942/ https://www.ncbi.nlm.nih.gov/pubmed/36915462 http://dx.doi.org/10.21037/jgo-22-113

Ejemplares similares

Sustained postoperative plasma elevations of plasminogen activator inhibitor-1 following minimally invasive colorectal cancer resection
por: Kumara, H.M.C. Shantha, et al.
Publicado: (2022)

Plasma Levels of Keratinocyte Growth Factor Are Significantly Elevated for 5 Weeks After Minimally Invasive Colorectal Resection Which May Promote Cancer Recurrence and Metastasis
por: Shantha Kumara, H. M. C., et al.
Publicado: (2021)

Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases
por: Shantha Kumara, HMC, et al.
Publicado: (2021)

Plasma and wound fluid levels of eight proangiogenic proteins are elevated after colorectal resection
por: Shantha Kumara, HMC, et al.
Publicado: (2019)

Plasma levels of the proangiogenic protein CXCL16 remains elevated for 1 month after minimally invasive colorectal cancer resection
por: Shantha Kumara, H. M. C., et al.
Publicado: (2018)

The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy
por: Kumara, H.M.C. Shantha, et al.
Publicado: (2021)

P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring
por: Kumara, H.M.C. Shantha, et al.
Publicado: (2017)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target
por: Shantha Kumara, HMC, et al.
Publicado: (2015)

Sclerotherapy needle injections can expand the subserosal and muscularis propria layers and cause a stable mucosal lift in ESD/EMR patients
por: Sandhu, Jaspreet, et al.
Publicado: (2018)

Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients
por: Ramos, Sofia C., et al.
Publicado: (2017)

Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
por: Hindy, George, et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor Levels in Tuberculosis Patients at High Risk for Multidrug Resistance
por: Mardining Raras, Tri Yudani, et al.
Publicado: (2012)

Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis
por: Butt, Sheraz, et al.
Publicado: (2021)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters
por: Ventorp, Filip, et al.
Publicado: (2015)

Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity
por: Can, Ummugulsum, et al.
Publicado: (2017)

Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection
por: Tsai, Ming-Chao, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients
por: Padelli, Mael, et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis
por: Özdirik, Burcin, et al.
Publicado: (2022)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders
por: Vasarhelyi, Barna, et al.
Publicado: (2016)

Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia
por: Tsai, Ping-Kun, et al.
Publicado: (2019)

Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer
por: Loosen, Sven H., et al.
Publicado: (2020)

Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience
por: Infantino, Maria, et al.
Publicado: (2022)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
por: Kotsiou, Ourania S., et al.
Publicado: (2022)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
por: Sugioka, Koji, et al.
Publicado: (2012)

Relationship of Circulating Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels to Disease Control in Asthma and Asthmatic Pregnancy
por: Ivancsó, István, et al.
Publicado: (2013)

Plasma Levels of Soluble Urokinase-Type Plasminogen Activator Receptor Associate with the Clinical Severity of Acute Puumala Hantavirus Infection
por: Outinen, Tuula K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_juhlff1lsbs5h7f14pac1q4rlp